Eisai Expands UK Manufacturing Capabilities, Driving New Career Opportunities in Life Sciences

Eisai Co., Ltd. announced a strategic investment supported by the UK Government under the Life Sciences Innovative Manufacturing Fund (LSIMF), subject to terms and conditions, at its manufacturing site in Hatfield, Hertfordshire, United Kingdom, to establish supply chain and packaging capabilities for current and future medicines that require cold-chain management, including lecanemab.

LSIMF is a capital grants scheme designed to strengthen life sciences manufacturing capabilities in the UK and enhance supply resilience against future health emergencies. The investment aligns with the UK Government’s policy to reinforce domestic pharmaceutical manufacturing and reflects Eisai’s long-term commitment to the United Kingdom.

Haruo Naito, Chief Executive Officer at Eisai Co., Ltd., said, “This strategic investment reflects our longterm commitment to strengthening resilient supply capabilities for our innovative medicines and pipeline products, while further deepening our long-standing relationship with the United Kingdom. We greatly value the opportunity to work collaboratively with the UK Government in strengthening life sciences manufacturing and healthcare resilience for the future.”

Science Minister Lord Vallance said, “Building world-class manufacturing capabilities here in the UK will secure the supply of vital medicines, including treatments for Alzheimer's disease, that can transform lives. Eisai's government-backed investment will also support the creation of new skilled jobs in Hatfield and is another example of the benefits of international companies investing in the UK – bolstering our reputation
as a life sciences hub while growing our economy.”